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ABSTRACT
The Brn-3a and Brn-3b transcription factor have
opposite and antagonistic effects in neuroblastoma
cells since Brn-3a is associated with differentiation
whilst Brn-3b enhances proliferation in these cells.
In this study, we demonstrate that like Brn-3a, Brn-
3b physically interacts with p53. However, whereas
Brn-3a repressed p53 mediated Bax expression but
cooperated with p53 to increase p21
cip1/waf1, this
study demonstrated that co-expression of Brn-3b
with p53 increases trans-activation of Bax promoter
but not p21
cip1/waf1. Consequently co-expression of
Brn-3b with p53 resulted in enhanced apoptosis,
which is in contrast to the increased survival and
differentiation, when Brn-3a is co-expressed with
p53. For Brn-3b to cooperate with p53 on the Bax
promoter, it requires binding sites that flank p53
sites on this promoter. Furthermore, neurons from
Brn-3b knock-out (KO) mice were resistant to
apoptosis and this correlated with reduced Bax
expression upon induction of p53 in neurons lacking
Brn-3b compared with controls. Thus, the ability of
Brn-3b to interact with p53 and modulate Bax
expression may demonstrate an important mecha-
nism that helps to determine the fate of cells when
p53 is induced.
INTRODUCTION
The Brn-3b POU transcription factors was isolated from ND7
neuroblastoma cells by its homology to the highly conserved
POU domain of Brn-3a. However, these distinct proteins
show limited homology outside the POU domain and often
display different functions in cells (1,2). For instance, in neu-
roblastoma cells, Brn-3a and Brn-3b demonstrate opposite
expression and antagonistic functions since Brn-3a increases
survival but induces differentiation of these cells whereas,
Brn-3b is associated with increased growth and proliferation
(3–5). In support of these observation, Brn-3b is elevated in
many neuroblastoma tumours as well as in breast cancers
(6,7). When increased in these cells, Brn-3b enhances cell
proliferation in vitro and tumour growth in vivo in xenograft
models (6,8) but also increases cell migration and confers
resistance to growth arrest stimulus. In contrast, reducing
Brn-3b levels in these cells is sufﬁcient to slow many of these
growth effects. However, Brn-3b appears to act in a complex
manner since loss of this protein in knock-out (KO) mice
result in signiﬁcant loss of retinal ganglion cells and conse-
quent blindness (9,10). The requirement for Brn-3b for speci-
ﬁcation, survival and differentiation in retinal ganglion cells,
is in contrast to its growth promoting effects in cancer cells,
suggesting distinct mechanisms by which this protein can act,
depending on the speciﬁc cells that expresses it.
The distinct and often antagonistic effects of Brn-3b and
Brn-3a in controlling growth of neuroblastoma cells, relates
to their effects on speciﬁc target genes (1,11,12). Thus,
whereas Brn-3a activates promoters of genes associated
with differentiation in these cells (e.g. SNAP25; neuroﬁla-
ment; a-internexin), Brn-3b either represses these promoters
or has no signiﬁcant effects on their activity (12–17). In con-
trast, Brn-3b modulates expression of genes that are associated
with proliferation e.g. it activates the cell cycle dependent
kinase (cdk4) promoter and accordingly Brn-3b correlates
well with cdk4 levels in tumours (18). Brn-3b also directly
represses the BRCA1 tumour suppressor gene which would
normally induce cell cycle arrest in breast cancer cells
(7,19–21). However, in addition to its direct effects on gene
transcription, Brn-3b also interacts with other cellular proteins
to modulate transcription indirectly. For instance, Brn-3b
physically associates with the estrogen receptor (ER) and
enhances its effects on an ERE containing promoter (22).
This was demonstrated on the HSP27 promoter which can be
directly transactivated by Brn-3b but maximal stimulation of
HSP27 expression in breast cancer cells requires cooperation
between Brn-3b and the ER (23). Thus, the interaction of
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co-expressed, is likely to inﬂuence its regulation of target
genes and hence cell fate.
Previously, we showed that Brn-3a (24) physically
interacts with the p53 protein (25) and alters its effects on
cell fate determination by differentially regulating the expres-
sion of different classes of p53 target genes (26–28). When
expressed, p53 determines cell fate by either inducing apop-
tosis or cell cycle arrest/DNA repair, and this is achieved
by its ability to regulate different subsets of genes (29).
Thus the stimulation of factors such as p21
cip1/waf1,
GADD45 and 14-3-3s are associated with cell cycle arrest/
DNA repair, whereas other target genes such as Bax, Apaf-
1, PUMA and Noxa that are increased in a p53 dependent
manner are associated with apoptotic responses (30,31).
However, the effects of inducing p53 expression are depen-
dent on cell type and growth conditions/stresses (e.g. DNA
damage) and its responses are greatly inﬂuenced by other pro-
teins that are co-expressed with it (28,32). Thus, co-
expression of p53 with proteins such as ASPP1/2, enhances,
expression of pro-apoptotic target genes (e.g. Bax; Apaf1)
and increases cell death (32,33). In contrast, co-expression
of Brn-3a with p53 antagonizes transcription of pro-apoptotic
target genes such as Bax and Noxa, whilst enhancing p53
mediated transcription of p21
cip1/waf1 gene associated with
cell cycle arrest (26--28). Consequently, co-expression of
Brn-3a with p53 results in increased survival and cell cycle
arrest when compared with p53 alone.
The interaction of Brn-3a with p53 occurs via the POU
domain of Brn-3a and the DNA binding domain of p53
(25). The POU domains of Brn-3b and Brn-3a share  95%
homology so we tested whether Brn-3b could also interact
with p53. In this study, we demonstrate the physical interac-
tion of proliferation associated Brn-3b transcription factor
with the p53 protein and show the functional effects of this
association on transcription of speciﬁc p53 target genes.
Although high levels of Brn-3b acts to increase growth of
some cancer cells we show that upon co-expression with
p53, Brn-3b can cooperate with p53 to enhance the pro-
apoptotic gene, Bax and so increase apoptosis in these cells.
MATERIALS AND METHODS
Expression vectors
The p53 expression construct (p53 cDNA cloned into
pcDNA3 expression vector) was a kind gift of Dr K. Vousden
(Beatson Institute for Cancer Research, Glasgow). Brn-3b or
Brn-3a cDNA cloned into pLTR expression vectors were
described previously (60).
Antibodies. Primary Antibodies: Brn-3b (Goat pAb) (Santa
Cruz, California, USA) orRabbit pAb (BAbCo—now unavail-
able); a-Bax Ab (Pharminagen, BD Biosciences, 1:500 dilu-
tion used at 1:1000--1:1500; a-actin Ab (Calbiochem, I 19)
used at 1:1500; a-p53 Ab (Abcam, ab4060) 1:1000 dilution;
a-Brn-3a Ab (Chemicon, MAB1585) 1:500–1000. a-cleaved
caspase-3 (Asp175—Cell Signaling Technology) used at
1:500 dilution. Phycoerythrin (PE) conjugated Annexin V
R&D Systems (Germany), a-Bax (Ab6) and a-p21
CIP1/Waf1
(Ab4) mAb were obtained from Oncogene Sciences.
Secondary antibodies: Peroxidase conjugated secondary
antibodies (a-rat, anti-mouse, -rabbit and -goat) were
obtained from DAKO (UK); used at dilutions of 1:3000–
2000).
Protein–protein interaction studies
Affinity Chromatography (Pull-down) assays. ‘Pull down’
assays were carried out as described (25). Brieﬂy, Brn-3b
GST fusion proteins linked to glutathione Sepharose beads
were equilibrated and stored in NETN buffer (100 mM
NaCl, 1 mM EDTA, 20 mM Tris (pH8), 0.5% Nonidet
P-40, 0.5% milk powder). For interaction studies, 1–2 mgo f
fusion protein were washed in transcription buffer (20 mM
HEPES (pH 7.9), 60 mM NaCl, 1 mM DTT, 6 mM MgCl2,
8.2% glycerol and 0.1 mM EDTA) resuspended in 100 ul
of the transcription buffer, then incubated for 1 h at room
temperature with 3–5 ul of
35S-methionine labeled in vitro
translated p53 proteins (FL or truncated proteins) prepared
using the TNT reticulocyte lysate kit (Promega). The equiva-
lent amount of the T7 luciferase protein provided with the
TNT kit was used as a control. Following 5· washes in
NETN buffer to removed non-interacting proteins in vitro
translated proteins, the pellets of the beads with interacting
proteins were boiled in Laemmli SDS loading buffer for
5 min then resolved on a 12% SDS–PAGE gel. The gel
was vacuum dried then exposed to radiographic ﬁlm.
Immunoprecipitation (IP). IP studies to demonstrate interac-
tion of Brn-3b with p53 (with appropriate controls) was car-
ried out as described (25). Brieﬂy, 5 mg of primary anti-p53
antibody were used to immuno-precipitate p53 protein
complexes from nuclear extracts prepared from ND7 cells
either expressing endogenous proteins or transfected to
over-express Brn-3b protein [Brn-3b(+)]. The ER antibody
was used as a positive control to IP Brn-3b whilst secondary
antibody only was used as negative control. Protein A or G
Sepharose beads were used to immobilize the antibody
bound proteins and washes were performed to remove
unbound proteins. Following the IP, proteins were resolved
on a 12% PAGE gel and subjected to western blot analysis
using the Brn-3b antibodies.
In the reciprocal study, to test whether p53 could be immu-
noprecipitated in complex with Brn-3b, speciﬁc Brn-3b pAb
were used for similar IP studies and studies with Brn-3a
(mAb) was included as positive control. IP of Brn-3-
containing complexes was undertaken using cellular extracts
prepared from ND7 cells co-transfected to over-express either
Brn-3a and p53 or Brn-3b and p53. Anti-actin antibody (goat
pAb) was used as IP control to conﬁrm speciﬁcity of interac-
tion with Brn-3b. Proteins obtained following IP were
resolved by PAGE and immunoblotted for either p53 or
Brn-3b (25).
Analysis of protein levels. Total cellular proteins were
prepared from either transiently or stably transfected cell
lines by harvesting into 2· Laemmli Buffer (+5% b-
mercaptoethanol or 1 mM DTT). Samples were heated to
95 C for 5 min then cell debris removed by centrifugation.
Variation in protein concentration was assessed using
Bradford assay or Coomassie blue stained PAGE gel, which
allowed visualization of the protein integrity as well as
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Western blot analysis was carried out as previously
described using 50–100 mg of each protein sample, which
were resolved by polyacrylamide gel electrophoresis on a
15% PAGE gel at a constant voltage of 150V (23). Proteins
were transferred onto Hybond C membrane using a wet-
transfer method as described by Maniatis et al. (61). Filters
were incubated with the appropriate primary antibody while
anti-actin antibody was used to equalize for protein loading.
Peroxidase conjugated secondary antibodies (anti-rat and
anti-goat) were used at dilutions of 1:3000 or 1:2000. Signals
were developed using the enhanced chemiluminescence
systems (Amersham PLC or Pierce, UK).
Cell culture, transfection and luciferase assays
The ND7 cell line, which was obtained by immortalization of
primary sensory neurons from DRG (62), was grown in full
growth medium (FGM) (L15 medium with 10% (v/v) foetal
calf serum (FCS) supplemented with D-glucose and glutamine
as described previously (63). Transient transfections were
carried out using either the Fugene 6 Transfection Reagent
(Roche) or GeneJuice  Transfection Reagent (Merck)
according to the manufacturer’s protocol. For transfections,
ND7 cells were plated at a density of 5 · 10
5 in 6 well plates
and incubated overnight (5% CO2,3 7  C in a humidiﬁed incu-
bator). Three hours prior to transfection, the medium was
changed to DMEM + 10% FCS.
Brn-3b over-expressing or vector control MCF7 cells were
maintained in DMEM + 10% FCS containing antibiotic G418
(800 mg/ml) to maintain selection of stably transfected cells.
For reporter analysis, 0.5 mg of reporter plasmid (WT Bax
or p21
cip1/waf1 or mutant Bax promoter with altered Brn-
3 site) was co-transfected with 0.5 mg of each of p53 or
Brn-3b or Brn-3a expression vector either alone or together
as indicated. The total amount of DNA was kept constant
in each experiment by using herring sperm DNA to adjust
for different amounts of reporter or expression vector added
to each experiment. The reporter construct with empty
expression vectors was used as a control and 0.05 mgo ft k
renilla luciferase construct was included in all transfections
to control for transfection efﬁciency. When piﬁthrin–a hydro-
bromide (Tocris, Bristol, UK) (64) was used to inhibit p53
expression, this was added to transfected cells at a ﬁnal
concentration of 10 mM when medium was change after 6 h
following transfection.
For luciferase assays, cells were harvested 48 h following
transfection using the passive lysis buffer (Promega) and
assay for ﬁreﬂy and renilla luciferase products measured
using the Dual-Luciferase  Reporter Assay System according
to the manufacturer’s protocol (26). Following adjustments
for differences in transfection efﬁciencies using renilla luci-
ferase activity, values were expressed as a percentage of the
vector control to show promoter activity upon co-transfection
with appropriate proteins.
Cell cycle analysis and measurement of Annexin
V positive cells
For cell cycle analysis and viability assays, cells were
transfected as described above together with an expression
vector containing the cDNA encoding the green ﬂuorescent
protein (GFP). 30--40 h following transfection, cells were har-
vested. For the analysis of cell cycle, transfected cells were
ﬁxed in 80% ethanol, stained with propidium iodide
(50 mg/ml with 500 mg/ ml RNAse A added) and the DNA
content was then measured by ﬂuorescence-activated cell
sorting (FACS) using the Beckman Coulter Epics XL and
analyzed using Expo32 software as previously described (25).
For measurement of Annexin V positivity, cells were
harvested by scraping into medium, pelleted by low speed
centrifugation, washed in cold PBS followed by a wash
with Annexin V buffer (Sigma). Cells were then incubated
with PE conjugated Annexin V (10 mlo f3 0mg/ml stock/
1 · 10
5 cells) in the dark for 15 min then analyzed by
FACS immediately. GFP expressing Annexin V positive cells
were counted and used as a measure of transfected cells
undergoing early apoptosis.
Chromatin immuno-precipitation (ChIP) assay
To test whether Brn-3b can be immunoprecipitated when
bound to p53 on the WT Bax promoter, ChIP analysis was
undertaken. This technique was carried out as described by
Lee et al. (23) using stably transfected MCF7 cells that
over-expressed Brn-3b compared with vector only transfected
cells. Cells plated at a conﬂuence of 1 · 10
6,i n1 0c m
2 Petri
dishes, were subjected to cisplatin treatment for 6 h after
which they were processed for ChIP analysis. Following
cross-linking, cells were harvested in cold phosphate buffered
saline (PBS) washed, then lysed in lysis buffer (1% SDS, 0.01
M EDTA; 0.05 M Tris, pH 8.0 and 0.01% protease inhibitor
cocktail). DNA was sheared by sonication and following cen-
trifugation, a volume of supernatant retained for use as
‘input’ sample in subsequent PCR analysis whilst the remain-
ing sample was divided and then subjected to IP overnight
using the appropriate antibody [either Brn-3b goat polyclonal
Ab (Santa Cruz) or the secondary anti-goat antibody (Dako,
UK)]. Protein G Sepharose beads were used to immobilize
protein-antibody complexes, which were washed thoroughly
then eluted from the beads. Cross-linking was reversed by
incubation at 65 C for 4 h and the proteins were digested
using proteinase K. Following phenol/chloroform extraction,
the DNA was precipitated with ethanol, then resuspended in
water and used for PCR. The primers used in the PCR to
amplify a 152 bp fragment of the promoter containing the
Brn-3 site are BaxF:50-CAAACAGAAAAGCAGGCCTGG-
30; BaxR: 50-GAGTGGTTTTGTTTTTTGCAGAGA-30.
Standard conditions were used for PCR ampliﬁcation and
included the use of 2.5 mM MgCl2 with the following cycling
parameters, 1 cycle at 94 C for 15 min followed by 40 cycles
of 95 C for 45 s; 60 C for 45 s and 72 C for 45 s. The reac-
tion was completed by an incubation of 72 C for 5 min. PCR
products were resolved on a 2.5% agarose/TAE gel.
DRG cultures
Brn-3b KO mice were described by Gan et al. (48) and
were kindly provided by Mengqing Xiang (Center for
Advanced Biotechnology and Medicine, Rutgers University,
New Jersey). Heterozygote crosses were used to give rise to
WT, heterozygote and homozygote offspring and mainte-
nance of this strain was in compliance with the home ofﬁce
6642 Nucleic Acids Research, 2006, Vol. 34, No. 22regulations. Genotyping was carried out using established
PCR protocols with speciﬁc primers to detect Brn-3b and
neomycin gene in genomic DNA prepared from tail tips.
Cultures of neurons from DRG were prepared at postnatal
day 1 from litters that contain Brn-3b homozygous, Brn-3b
heterozygous or WT offspring. The cultures were prepared
using methods previously described (40). Brieﬂy the mice
were sacriﬁced and the tails removed for genotyping after
the experiments to enable non bias blind counting. The gan-
glia were dissected out and then dissociated in 0.3% collage-
nase and 0.1% trypsin for 20 min. Excessive non-neuronal
cells were removed by centrifuging the dissociated cells
through a 6% metrizamide cushion (Sigma M3383). Pelleted
neurons were resuspended in deﬁned media with 10 ng/ml
NGF and plated onto laminin coated coverslips. Neuronal
death was induced after 24 h in culture by NGF withdrawal
in some cultures whilst control cultures continued to be
grown in medium containing NGF. Cell were either harvested
for RNA in 100 ul of Trizol (Sigma) and processed according
to the manufacturer’s protocol or observed for viability. This
was assessed on the basis of morphology with live cells
showing an intact nucleus and a rounded phase bright body
whereas dead cells were identiﬁed by a dark, granular nucleus
and an absence of phase bright ring around the neuron body.
All scoring was done blind, prior to genotyping of stored
tail DNA. Cell count after 48 h treatment is expressed as per-
centage of count at start of treatment. All data are represented
as mean + SEM. An asterisk indicates P < 0.001 versus
control, according to a two-tailed Student t-test.
Quantitative RT–PCR (qRT–PCR)
To analyze for changes in mRNA encoding genes of interest,
total cellular RNA was prepared from different cells follow-
ing the treatments described using Trizol reagent (Sigma) and
the protocol previously described (18,65). To analyze for
changes in mRNA of speciﬁc target genes, qRT–PCR was
undertaken using Taqman MGB probes. The Assay-on-
Demand probe/primer mix Hs00180269-m1 was used for
analysis of Bax mRNA and 99999905 used for ampliﬁcation
and quantiﬁcation of GAPDH (Applied Biosystems—http://
www.appliedbiosystems.com/). The reaction was carried out
according to the Assay-on-Demand protocol but using Quan-
tiTect Probe mastermix (Qiagen—http://www1.qiagen.com/).
RESULTS
Brn-3b protein associates with p53 via the POU domain
The high homology in POU domains of Brn-3b and Brn-3a
protein lead us to test whether Brn-3b also interacted with
the p53 protein. Afﬁnity chromatography ‘pull-down’ assays
were undertaken using Brn-3b GST fusion protein, immo-
bilized on Sepharose beads and incubated with in vitro trans-
lated (IVT) wild type (WT) p53 protein. The ER was used as
a positive control whilst the non-related IVT luciferase
protein was used as a negative control. As shown in
Figure 1A, incubation of Brn-3b GST with p53 IVT resulted
in a signiﬁcant percentage of the p53 protein being retained
by Brn-3b (11.5% of input). This was comparable to the posi-
tive control ER protein that is known to interact with Brn-3b
(15.2% of input). The associations of Brn-3b with p53 and
ER IVT were speciﬁc as the IVT control (luciferase) protein
was not retained by Brn-3b and neither p53 nor ER proteins
were retained by the GST moiety alone.
The POU domain of Brn-3a interact with DBD of p53 and
the high homology between the POU domain of Brn-3b and
Brn-3a suggests that the POU domain of Brn-3b should inter-
act with the DNA binding domain of p53. Therefore, similar
studies were next undertaken to identify the domains of Brn-
3b and p53 required for this interaction. Thus, the isolated
Brn-3b POU domain linked to GST (Brn-3b POU–GST)
was incubated with IVT full length (FL) p53 as well as trun-
cated forms of the p53 protein [shown in Figure 1B(i)]. In
our previous experiments to study Brn-3a/p53 interaction,
two truncated proteins (1–106 and 1–228), which lacked the
DNA binding domain (DBD) of p53, had failed to bind to
Brn-3a but deletion construct, p53(44–393), lacking the N0
terminal transactivation domain but with the DBD intact,
could still effectively interact with Brn-3a (25). Therefore,
these constructs were used in this study to test whether the
p53 DBD was required for interaction with Brn-3b POU
domain. As expected, FL p53 protein interacted with Brn-
3b POU domain with high relative afﬁnity [Figure 1B(ii)].
However, the two constructs lacking the DBD (1–106 and
1–228) failed to be retained by Brn-3b POU domain. In con-
trast, p53 (44–393), lacking the N0 terminal trans-activation
but with intact DBD could effectively bind to Brn-3b.
Thus, as with Brn-3a (25), the Brn-3b POU domain is sufﬁ-
cient to interact with p53 and this requires the C0 terminal
region of p53 protein that contains the DBD.
To determine whether the interaction of Brn-3b with p53
can also be observed in intact cells, we tested whether
these proteins could be immuno-precipitated (IP) in complex
from cellular extracts that co-express both proteins. Nuclear
extracts were obtained from ND7 cells that either expressed
endogenous Brn-3b or that were transfected with the expres-
sion vector encoding the 32 kDa Brn-3b(s) protein to increase
the levels of this protein (+). Immuno-precipitation (IP) was
carried out using either anti-p53 antibody or the positive
control anti-ER, antibodies which was previously used to
effectively immuno-precipitate Brn-3b. Secondary antibody
alone was used as a negative control. The IP complexes
were resolved by PAGE and the immunoblots were probed
with Brn-3b antibody [shown in Figure 1C(i)]. As expected,
Brn-3b was successfully immunoprecipitated with the ER
antibody in cells with endogenous Brn-3b protein (E) and
with transfected Brn-3b (+). Similarly, IP with anti-p53 anti-
body resulted in Brn-3b being retained in complex with p53.
Quantiﬁcation of the relative amount of Brn-3b that was IP
with p53 was carried out by scanning densitometry. These
results showed that IP using cellular extracts from cells trans-
fected to over-express Brn-3b protein (+) resulted in a 2-fold
increase of the Brn-3b protein (4.55 arbitrary units) when
compared with cells expressing endogenous Brn-3b (E)
(2.29 arbitrary units). Brn-3b did not immuno-precipitate
with the negative control antibody conﬁrming the speciﬁcity
of the interaction with p53.
In the reciprocal study, we tested whether p53 could also be
immunoprecipitated with Brn-3b by undertaking similar stud-
ies using a-Brn-3b antibodies and cell extracts obtained
fromND7cellstransfectedwithBrn-3b(orBrn-3aforcontrol).
a-Brn-3aantibodieswereusedaspositivecontrol(+vecontrol)
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resolvedbyPAGEwereimmunoblottedwithanti-p53antibody
to detect p53 protein. As shown in Figure 1C(ii), p53 was suc-
cessfullyisolatedincomplexwithbothBrn-3aandBrn-3bpro-
teins but not using anti-actin antibody ( ve control). These
results conﬁrmed that Brn-3b does indeed interact with p53
in these neuroblastoma cells.
Brn-3b enhances cell death but not cell cycle arrest
when co-expressed with p53
Since Brn-3b is associated with proliferation in ND7 cells (5),
whilst high levels of p53 induces either cell cycle arrest or
apoptosis (28), we next tested the effects of co-expressing
Brn-3b with p53 on the fate of these cells. Cells were co-
transfected with Brn-3b or p53 either alone or both together.
GFP expressing vector was included in all experiments to
mark transfected cells. Brn-3a + p53 was included as positive
control whilst transfection of the empty expression vector
was used to establish baseline activity. To measure trans-
fected cells undergoing early apoptosis, FACS analysis was
undertaken following annexin V staining of cells, 30 h after
transfection. (see Material and Methods section). Changes
in viable cells were expressed relative to vector control
(value arbitrarily set at 1).
Figure 1. Interaction of Brn-3b protein with p53, in vitro and in vivo.( A) Affinity chromatography (pull-down) analysis using full length Brn-3b GST fusion
protein and
35S labelled IVT to show interaction of Brn-3b with p53. The p53 IVT protein was efficiently retained by Brn-3b (lane 2) showing similar affinity to
positive control ER (lane 3) previously shown to interact with Brn-3b. The IVT luciferase protein (–ve control) was not retained by Brn-3b (lane 1). This
interaction was specific to Brn-3b as none of the IVT proteins were retained by the GST moiety only. (B) (i) Schematic representation of the p53 deletion
constructs used to identify the region of p53 required for interaction with Brn-3b POU domain. The positions of the amino acid shown represent those that are
present with the deletions; AD, activation domain; DBD, DNA binding domain; OD, oligomerization domain (ii) Affinity chromatography analysis using Brn-3b
POU–GST fusion protein showed that the isolated POU domain was sufficient to interact with WT FLp53 (lane 1). Use of the IVT truncated p53 constructs
demonstrated that the amino acids between 1 and 106 (lane 2) or 1 and 228 (lane 3) of p53 were insufficient to mediate interaction with Brn-3b but the truncated
protein, 228–393 lacking only the amino terminus (lane 4) could interact with affinity similar to the FLp53 protein. One-tenth of the input of IVT proteins used
for the ‘pull-down’ assays are shown in the next panel (lanes 5–8) and * is used to indicate the size of expected polypeptide following IVT of the truncated
constructs. (C) Co-immunoprecipitation assay demonstrating that Brn-3b can be isolated as a complex with p53 protein from cellular extracts. (i) IP undertaken
using cellular extracts taken from neuroblastoma cells with endogenous Brn-3b (E) or with transiently transfected with Brn-3b (+), using antibodies to either ER
(ER Ab) or p53 (p53 Ab) resulted in isolation of Brn-3b protein which was detected by western blotting. The control antibody ( ve) did not result in IP of
Brn-3b. The isolated Brn-3b proteins are indicated by * and shows the shorter Brn-3b protein ( 32 kDa) and longer 43 kDa Brn-3b isoforms (very weakly). The
non-specific bands indicated by less than appear to be associated with use of the protein A/G Sepharose to immobilize the antibody bound proteins.
(ii) Immunoprecipitation of p53 with either Brn-3a or Brn-3b from cellular extracts prepared from ND7 cells transfected with Brn-3a and p53 (lane 2) or Brn-3b
and p53 (lane 3). The p53 protein was detected by western blotting. The p53 protein did not immuno-precipitate with the control actin antibody ( ve) (lane 1).
6644 Nucleic Acids Research, 2006, Vol. 34, No. 22Figure 2A(i) shows the representative changes seen in
the proportion of apoptotic (annexin V positive) transfected
(GFP positive) cells in independent experiments. 30–40%
of cells transfected with the empty vector [Figure 2A(i)
LTR] were undergoing apoptosis. This is in line with previ-
ous studies undertaken with these cells (28) and compares
with apoptosis in  10–20% of untransfected cells [measured
by percentage of annexin V positive cells in normally prolif-
erating cells (data not shown)]. As expected, increasing p53
levels resulted in increased apoptosis (p-0.023) compared
with control transfected cells whereas Brn-3b alone did not
increase apoptosis. However, co-expression of Brn-3b with
p53 resulted in signiﬁcantly enhanced apoptosis in these
cells compared with p53 alone or controls (p-0.049). As
expected from (previous studies), co-expression of p53 with
Brn-3a was protective since cell death was decreased when
compared with vector control, Brn-3a or p53 alone.
Figure 2A(ii) shows that these effects were also observed in
independent experiments using MCF7 cells which express
Brn-3b and wt p53 (6,34). Thus in MCF7 cells, increasing
p53 alone did induce apoptosis compared with vector control.
However, although Brn-3b alone did not alter cell death, co-
expression of p53 with Brn-3b resulted in further signiﬁcant
increases in the proportion of apoptotic cells.
Since p53 could also induce cell cycle arrest in ND7 cells,
we next tested whether Brn-3b changes this function of p53
by measuring the percentage of transfected (GFP positive)
cells that were in the G0/G1 phase of the cell cycle. Asyn-
chronously growing ND7 cells were used for these studies
and ﬁgure 2B shows that 20–30% of control (LTR) trans-
fected cells were in G0/G1 phase of the cell cycle, in line
with previous results seen with this cell line. Expression of
Brn-3b alone did not alter the percentage of cells that were
arrested in the G0/G1 phase of the cycle compared with
control cells and its co-expression with p53 did not signiﬁ-
cantly affect cell cycle arrest induced by p53 alone. In con-
trast, as expected, Brn-3a enhanced the percentage of cells
arrested in G0/G1, and this is markedly increased when
Brn-3a was co-expressed with p53. Although p53 can induce
arrest in G2 (35), these effects of Brn-3a were primarily
observed in G1 phase of the cell cycle.
Therefore, co-expression of Brn-3b with p53 in ND7 cells
appear to enhance death but did not alter cell cycle arrest
function of p53, in contrast to the related Brn-3a protein,
which enhanced cell survival and cell cycle arrest when
co-expressed with p53 (28).
Brn-3b enhances trans-activation of Bax promoter
by p53
Since the related Brn-3a protein could differentially regulate
transcription by p53 on target promoters such as bax and
p21
cip1/waf1, we next tested whether co-expressing of Brn-3b
Figure 2. Co-expression of Brn-3b with p53 increases apoptosis but did not alter cell cycle arrest in ND7 cells (A) (i) Representative changes in early apoptotic
(annexin V positive), transfected (GFP positive) ND7 neuroblastoma cells as measured by FACS analysis following transfection of cells with either p53, or Brn-3b
or Brn-3a alone, or p53 co-transfected with either Brn-3b or Brn-3a control. Whereas p53 alone increased percentage of apoptotic cells; this was significantly
increased upon co-expression with Brn-3b compared with p53 alone (denoted by **). In contrast, co-transfection of the positive control Brn-3a with p53 leads to
protection from apoptosis. Data is expressed relative to LTR control (set at 1) and represents the mean ± standard error from three independent experiments.
Statistical significance was determined using Students t-test. (ii) Similar effects were seen in MCF7 cells transfected with Brn-3b or p53 either alone or together.
p53 alone resulted in increased cell death compared with control transfected cells (LTR) but upon co-expression of Brn-3b with p53, the percentage of apoptotic
cells was increased. (B) Analysis of changes in the percentage of transfected cells undergoing cell cycle arrest (in G0/G1) following transfection with p53 and/or
Brn-3b.Brn-3a+ p53 wasincludedasthe positivecontrol.DNAcontent wasmeasured byFACS analysisfollowingpropidiumiodide labeling.Althoughp53 alone
resulted in a small increase in cells accumulating in Go/G1 phase of the cell cycle, co-expression Brn-3b did not alter its effects compared with the significant
changes seen upon co-expression of p53 with Brn-3a. The results represent mean (± SE) of percentage of GFP positive cells in the G0/G1 phase of the cell cycle in
four independent experiments.
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Co-expression of Brn-3a with p53 was used as a control.
Figure 3A shows that p53 strongly transactivated the
Bax promoter and as expected, this effect was signiﬁcantly
reduced when the related Brn-3a POU protein with co-
expressed with p53. In contrast, whereas Brn-3b alone rep-
ressed the bax promoter (46% ± 23 of basal activity seen in
LTR control transfected cells, set at 100%), co-expression of
Brn-3b with p53 resulted in signiﬁcant enhancement of the
promoter activity compared with p53 alone (1.7-fold increase
compared with p53 only; P-value < 0.005).
Similar studies were undertaken using the p21
cip1/waf1 pro-
moter. As shown in Figure 3B, Brn-3b alone had no effect on
this promoter (92% ± 30 of basal activity seen in control
transfected cells, LTR, set at 100%) and its co-expression
with p53 did not increase promoter activity but instead
resulted in a decrease (938 ± 259) compared with
p53 alone (1827 ± 506). As expected, Brn-3a cooperated
with p53 to enhance trans-activation of the p21
cip1/waf1 pro-
moter.
These results conﬁrm that Brn-3a and Brn-3b POU proteins
mediate different effects on gene expression when co-
expressed with p53 with Brn-3b and p53 cooperating on the
bax but not p21
cip1/waf1 promoter.
We next tested whether the cooperative effect seen upon
co-expression of Brn-3b with p53 on the bax promoter specif-
ically required the p53 protein by undertaking similar exp-
eriments in the presence (+) or absence ( ) of the p53
inhibitor, piﬁthrin-a-hydrobromide. As shown in Figure 3C,
the addition of piﬁthrin-a-hydrobromide resulted in a signiﬁ-
cant loss of p53 mediated transcription of this promoter. Fur-
thermore, co-expression of Brn-3b with p53 failed to give rise
to the increased activation previously seen on this promoter.
These results therefore suggest that Brn-3b requires expres-
sion of functional p53 in order to stimulate bax promoter
activity.
Figure 3. Co-expression of Brn-3b with p53 increases Bax promoter activity but did not alter p21
cip1/waf1 promoter activity in ND7 cells (A) Effect of Brn-3b and
p53 expression vectors on expression of the Bax promoter driving a luciferase gene reporter in ND7 cells. p53 strongly activated the Bax promoter (lane 2), but
Brn-3a and Brn-3b mildly inhibited its basal activity (lanes 3 and 5) compared with the control vector (lane 1). As expected, Brn-3a repressed p53 mediated
activity of the promoter (lane 4), but co-transfection of Brn-3b with p53 (lane 6) resulted in a significant enhancement in promoter activity compared with p53
alone (lane 2) (P < 0.05). Values are expressed as a percentage of the empty LTR control vectors. All values were equalized on the basis of the activity observed
upon co-transfection with a control renilla expression vector. Values are the average of five experiments whose SD is shown by the bars. (B) Effect of Brn-3b
and/or p53 expression vectors on the activity of the p21
CIP1/Waf1 promoter driving a luciferase reporter gene in ND7 cells. As expected, p53 alone transactivated
the promoter (lane 2) and Brn-3a mildly activated the promoter (lane 3) but cooperated with p53 to enhance the promoter activity (lane 4) compared with p53
alone only (lane 2). However, Brn-3b alone had no effect on promoter activity (lane 5) but it appears to reduce p53 mediated activation on this promoter (lane 6)
compared with p53 alone. Values are expressed as a percentage of the activity obtained with the empty LTR expression vector alone (which was set at 100%). All
values were equalised on the basis of the activity of a control renilla reporter plasmid which was co- transfected in all cells. Values are the average of five
experiments ± SD (shown by error bars). (C) The ability of Brn-3b to increase Bax promoter activity is dependent on p53 since the p53 inhibitor, a-pifitrin,
prevented the transactivation seen by p53 alone (set 3) or upon co-operation of Brn-3b and p53 (set 4). The changes in promoter activity following treatment with
a-pifitrin are expressed as percentage of a-pifitrin treated LTR control (set at 100%) whereas induction in the absence of a-pifitrin is expressed as percentage of
untreated LTR control (also set at 100%).
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effects on the bax promoter
Previous studies using in vitro site-directed mutagenesis
showed that two binding sites which ﬂanked the p53 consen-
sus site in the bax promoter [shown in Figure 4A(i)] were
essential for Brn-3a to repress p53 mediated transactivation
of this promoter (27). We therefore tested whether loss
of these Brn-3 binding sites could also alter the ability of
Brn-3b to cooperate with p53 on this promoter. Thus, similar
co-transfection studies were undertaken using mutant bax
promoter that lacked both Brn-3 sites [Figure 4A(i)]. Results
of reporter assays using the mutated bax promoter are shown
in Figure 4A(ii) and demonstrated that Brn-3b, on its own,
fails to repress the mutated bax promoter (111% ± 60 of
basal activity seen in control LTR transfected cells, set at
100%). However, more interestingly, whilst p53 alone con-
tinue to transactivate this promoter, co-expression of Brn-
3b with p53 failed to cooperate and enhance the promoter
activity as seen with the WT promoter (Figure 3A). There-
fore, the intact Brn-3 binding sites in the bax promoter are
required for Brn-3b to cooperate with p53 to enhance tran-
scription of this gene.
In order to determine whether Brn-3b is bound to the bax
promoter in vivo in intact cells, under appropriate conditions,
we undertook Chromatin Immuno-precipitation (ChIP) assays
using Brn-3b over-expressing cells treated with cisplatin
to stimulate p53 expression. Figure 4B(i) shows that p53
mRNA is increased  2-fold following cisplatin treatment
comparedwithlevelsinuntreatedcells[(quantiﬁedusingquan-
titative (q)RT-PCR (see Material and Methods)]. Similarly,
Bax mRNA was increased in cisplatin treated cells com-
pared with untreated controls. These results conﬁrm that
p53 mRNA is induced by cisplatin treatment and is accom-
panied by elevation in bax mRNA expression.
ChIP assays were undertaken using Brn-3b antibody to
immunoprecipitate this protein bound to DNA of target
promoters in cisplatin treated Brn-3b over-expressing cells.
Figure 4B(ii) shows the PCR products obtained following
the ChIP analysis and demonstrates that IP of Brn-3b protein
cross-linked to DNA under these conditions resulted in suc-
cessful ampliﬁcation of a region in the Bax promoter that
contains the Brn-3 site. This effect was only observed follow-
ing IP with anti-Brn-3b antibody but not with the control
actin antibody. These results therefore conﬁrm that Brn-3b
is indeed bound to the bax promoter in intact cells and may
thus act by associating with p53 once it is bound to the
promoter.
Co-expression of Brn-3b with p53 increases endogenous
levels of Bax protein
Since co-expression of Brn-3b with p53 could signiﬁcantly
increase bax promoter activity, we next tested whether
Figure 4. Brn-3b binds to specific sites in the Bax promoter for cooperative effects with p53 (A) (i) Schematic diagram to show the positions of the p53 binding
site and the two Brn-3 binding sites within the promoter construct used that were altered in mutant Bax promoter. (ii) Reporter assays following co-transfection of
Brn-3b and / or p53 with mutant Bax promoter (mutated Brn-3 sites but intact p53 binding site) into ND7 cells showed that the Brn-3 sites within the Bax
promoter are required for Brn-3b to repress p53 mediated transcription of this promoter. Co-transfection of p53 resulted in transactivation of the bax promoter
(lane 2) compared with control (lane 1) but Brn-3b alone had little effect (lane 3) and also failed to cooperate with p53 to further enhance promoter activity (lane
4). (B) (i) Induction of p53 and bax mRNA following treatment of ND7 cells with cisplatin as measured by qRT–PCR. Following treatment with cisplatin p53
mRNA was increased by up to 2-fold compared with untreated cells (set at 1). Similarly bax mRNA showed a corresponding increase following treatment. The
results represent the mean (± SD) of three sets of treatments. (ii) Chromatin Immuno-precipitation (ChIP) of Brn-3b in cells treated with cisplatin to induce bax
expression resulted in significant binding of Brn-3b to a site within the bax promoter. Amplification of a 180 bp region of the promoter which flanks the Brn-3
and p53 sites resulted in a strong band (lane 4) comparable to the input lane (lane 2). ChIP using the control actin antibody did not give rise to this band following
PCR amplification (lane 3).
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would enhance endogenous Bax expression. Western blot
analysis was undertaken to analyze Bax protein levels using
cellular extracts prepared from cells transfected with Brn-3b
and p53, either alone or both together. This was compared
with control cells transfected either with the empty vector,
LTR or co-transfected positive control, Brn-3a + p53. As
shown in ﬁgure 5A(i), p53 alone increased the expression
of Bax protein when compared with LTR whereas co-
expression of p53 with control protein Brn-3a resulted in
decreased Bax expression compared with p53 only. Although
Brn-3b alone did not increase Bax levels, co-transfecting Brn-
3b and p53 together resulted in signiﬁcantly increased levels
of Bax protein compared with p53 alone. Figure 5A(ii) shows
Figure 5. Co-expression of Brn-3b with p53 increases endogenous Bax expression (A) (i) Changes in the levels of Bax protein following transfection of ND7
cells with Brn-3b and p53 (lane 6) compared with p53 alone (lane 3) or Brn-3b alone (lane 7). LTR vector alone (lane 1) or Brn-3a or p53 (lanes 2 and 3) are also
shown and compared with co-expression of Brn-3a and p53 (lane 4). The levels of control actin protein demonstrate protein loading in each transfected cell
population. (ii) Analysis of the levels of Brn-3b and p53 to show the increase in expressed Brn-3b levels when cells were transfected with Brn-3b (lanes 5 and 6)
or p53 (lanes 2, 4, 6) alone or in combination with other proteins. (iii) Analysis of bax and p21
CIP1/WAF1 proteins following co-transfection of Brn-3b with p53
demonstrates that Brn-3b only cooperates with p53 to increase Bax expression (top panel, lane 5) but not and p21
CIP1/WAF1(2nd panel, lane 5). This is compared
with the effects of Brn-3a and p53 (lane 2) or p53 (lane 1) (carried out in the same experiment). Actin was used to demonstrate variability in loading of protein
samples. (B) Changes in the expression of Bax mRNA in control or Brn-3b over-expressing MCF7 cells treated with cisplatin to induce WT p53. Lane 1 shows
the bax mRNA in untreated LTR control cells was set at 1. Following treatment, there is a 2-fold increase in bax mRNA in these control cells (lane2). Levels of
bax mRNA in untreated Brn-3b over-expressing cells (lane 3) was lower but this increased significantly following treatment with cisplatin (lane 4). mRNA was
quantified by qRT–PCR and variability in RNA from different treatment was equalized to GAPDH. The values represent the mean and SD from three
independent experiments. (C) Analysis of Bax mRNA expression in neuronal cultures obtained from DRG prepared from either WT or Brn-3b
 /  (KO) mice that
have been grown in the presence (+) or absence ( ) of NGF (to induce apoptosis). WT cultures showed an increase in Bax mRNA following withdrawal of NGF
(lane 2) compared with controls (+NGF, lane 1). DRG cultures prepared from Brn-3b KO mice showed a decrease in Bax mRNA (lane 3) and no increase even
upon NGF withdrawal (lane 4). Levels of the neuronal factor, GAP43 remains unchanged suggesting that the effect is specific to bax expression.
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the appropriate expression constructs. Figure 5A(iii) shows
that these effects were speciﬁc to Bax as co-expression of
Brn-3b and p53 did not change p21
cip1/waf1 protein levels
but co-expression of Brn-3a with p53 resulted in signiﬁcant
increases, as expected. These results therefore conﬁrm that
co-expression of Brn-3b with p53 increases endogenous
Bax protein levels in ND7 cells.
To test whether Brn-3b could cooperate with p53 to
increase Bax expression in other relevant cell types also,
we utilized Brn-3b over-expressing MCF7 breast cancer
cells (known to express WT p53) or control MCF7 cells
(LTR) which were either treated with cisplatin, to induce
p53 expression or left untreated. RNA prepared from treated
cells and untreated controls were used for cDNA synthesis
and real-time PCR (qRT–PCR) was undertaken to quantify
Bax mRNA levels. As shown in Figure 5B, treatment of con-
trol cells (LTR) with cisplatin, resulted in nearly 2-fold
increased bax mRNA in control cells which is expected
when p53 expression is induced (see Figure 4B). However,
there was signiﬁcant increase in the levels of bax mRNA in
Brn-3b over-expressing cells treated with cisplatin compared
with untreated Brn-3b over-expressing cells or in control
cells. These results therefore conﬁrm that induction of p53
expression in cells expressing high levels of Brn-3b results
in a signiﬁcant increase in bax mRNA in these cells also.
Brn-3b( / ) neuronal cultures that are resistant
to apoptosis express less Bax protein
Brn-3b is expressed in the dorsal root ganglion (DRG) and
neurons of the spinal cord where bax expression is essential
for apoptosis during neurogenesis (36–38). Previous studies
by Ensor et al. (39) showed that primary cultures of DRG
prepared from mice lacking Brn-3b [Brn-3b( / )] are highly
resistant to death-inducing stimuli, e.g. Nerve Growth Factor
(NGF) withdrawal which requires bax expression (37,38).
Since Brn-3b cooperates with p53 to enhance Bax expression
and hence increase apoptosis under certain conditions, we
tested whether the resistance to apoptotic stimulus in Brn-
3b( / ) neurons might be associated with reduced expres-
sion of pro-apoptotic Bax. Therefore, primary DRG cultures
prepared from Brn-3b KO mice and WT littermates (39,40)
were either grown in deﬁned medium that contained NGF
at concentration of 10 ng/ml( +) or were deprived of NGF
( ) which results in increased apoptosis in WT DRG cul-
tures. Analysis of mRNA encoding the Bax protein was deter-
mined by RT–PCR (see Materials and Methods section).
Figure 5C shows that bax transcripts were increased in
WT cultures grown in medium lacking NGF compared with
matched control cultures grown in the presence of NGF.
In contrast, cultures prepared from Brn-3b KO mice and
grown in full growth medium containing NGF showed reduc-
tion in bax mRNA. Furthermore, there was no induction in
bax expression even when the cultures from Brn-3b KO
were grown in medium lacking NGF. Although Bax levels
were reduced in the KO cultures compared with WT controls,
the structural protein GAP43 remained unchanged in WT and
KO cultures under these conditions.
Given the critical role for bax in controlling apoptosis in
these cells during development (36–38), these results suggest
that although Brn-3b on its own might inﬂuence survival
of neurons during development (10,41), if it is co-expressed
when p53 is induced in these cells, cooperation between
these two factors will result in maximal induction of Bax
and hence apoptosis.
DISCUSSION
Fate decision made by cells, in terms of whether they con-
tinue to proliferate, undergo cell cycle arrest or die, is crucial
during development as well as for normal tissue homeostasis /
functions. When induced, the p53 transcription factor, either
leads to cell cycle arrest or apoptosis and its ability to control
such events depends on which of its target genes are induced
under different cellular conditions (42–44). While many p53
dependent target genes have been identiﬁed, it is now clear
that transcriptional regulation of these target genes by p53
is highly dependent not only on the levels and localization
of p53, but also on other cellular proteins that are co-
expressed and physically associate with p53. For instance,
whilst ASPP1/2 proteins can enhance the expression of pro-
apoptotic p53 target genes such as Bax and Apaf1 (32,33),
co-expression of the differentiation-associated Brn-3a POU
protein with p53 results in antagonism on pro-apoptotic
Bax and Noxa promoters, but cooperation on p21
cip1/waf1 pro-
moter with consequent increased survival and cell cycle arrest
in neuronal cells (22–25).
In this study, we have shown that the related Brn-3b POU
protein also physically interacts with p53 via the POU
domain, a region with very high homology to Brn-3a. Dele-
tion constructs that lacked the DBD and C0 terminus of p53
failed to associate with Brn-3b, suggesting that this region
of the p53 protein is required for effective interaction with
Brn-3b. Because of the signiﬁcant similarity (95%) between
the POU domains of Brn-3a and Brn-3b (45), it is likely
that Brn-3b will bind p53 via the DBD. Moreover, like
Brn-3a, Brn-3b can be immunoprecipitated in complex with
p53 from cellular extracts, demonstrating a physiologically
relevant association of the Brn-3 proteins with p53 in intact
cells. However, analysis of the functional effects of co-
expressing Brn-3b with p53 showed that in contrast to Brn-
3a (which prevented p53 mediated cell death but supported
cell cycle arrest when co-expressed with p53 in these cells),
increasing both Brn-3b and wtp53 expression, enhanced cell
death in ND7 neuroblastoma cells compared with either factor
alone but did not signiﬁcantly alter cell cycle arrest caused by
p53. At the molecular level, Brn-3b can cooperate with p53 to
enhance the expression of the pro-apoptotic Bax promoter but
not the p21
cip1/waf1 promoter. This is in contrast to Brn-3a
which antagonized p53 mediated bax expression but coopera-
ted to enhance p21
cip1/waf1 expression. Consequently, co-
expression of Brn-3b with p53 resulted in increased endoge-
nous Bax protein expression compared with p53 alone or
with controls.
The stimulation of Bax expression in the presence of
Brn-3b requires wt p53, since on its own, Brn-3b represses
bax promoter activity but when it is co-expressed with p53,
bax promoter activity is signiﬁcantly enhanced. Although
the experiments in ND7 cells relied on over-expression of
exogenous Brn-3b and p53 and has to be interpreted with
Nucleic Acids Research, 2006, Vol. 34, No. 22 6649caution, we observed that induction of wt p53 in MCF7 cells
which express high levels of Brn-3b resulted in higher levels
of bax and accompanying apoptosis. This was also supported
by ﬁndings that the p53 inhibitor, piﬁthrin-a-hydrobromide,
prevented p53 mediated trans-activation of the Bax promoter
and abolished the cooperative effects of Brn-3b when it is
co-expressed with p53. Moreover the distinct effects of
Brn-3a and Brn-3b upon co-expression with p53 suggest
speciﬁc and signiﬁcant effects that are dependent on which
POU protein is co-expressed with p53.
The role for Brn-3b in regulating p53 mediated Bax
expression was also demonstrated in primary cultures of
DRG neurons prepared from Brn-3b KO mice. Thus, cultures
prepared from WT littermates underwent apoptosis upon
NGF withdrawal which is associated with increased bax
mRNA levels (39). However, this response was attenuated
in Brn-3b( / ) cultures, which showed signiﬁcantly reduced
death when grown under similar conditions (39), and this cor-
related with decreased Bax expression. This observation
highlights an important mechanism by which Brn-3b may
act to control cell fate during development. Brn-3b and the
related Brn-3a proteins are both expressed during develop-
ment in neuronal precursors and in speciﬁc neurons but evi-
dence so far suggest that they give rise to distinct effects. The
role for Brn-3a during neurogenesis in the PNS has been
widely studied and this transcription factor was shown to
be essential for survival and differentiation of speciﬁc neu-
rons since Brn-3a( / ) mutants suffer loss of somato-
sensory neurons during development with resultant early
lethality (46,47). Although Brn-3b has been identiﬁed as
being critical for survival and normal function of retinal gan-
glion cells (41,48), there is still much to be understood about
its expression and function during neurogenesis in the PNS.
Our ﬁndings showing that neurons cultured from Brn-3b
KO are resistant to apoptosis is very interesting particularly
in view of the decreased bax mRNA expression found in
these cells. It is known that p53 levels are increased during
neuronal development, when it is associated with either cell
cycle arrest or apoptosis (26,49–52). Furthermore, Bax
expression in DRG appears to peak between E13.5–15.5 coin-
cident with increased death in Brn-3a KO embryos, which
suffer signiﬁcant neuronal apoptosis during development
(36). A number of studies have shown that Bax plays a criti-
cal role in controlling apoptosis in sensory neurons of the
DRG. For instance, DRG neurons fail to undergo apoptosis
in bax KO mice (38,53) and in vitro cultures of DRG neurons
prepared from bax KO mice survived in the absence of the
neurotrophic support, NGF which induces widespread apop-
tosis in WT cultures (37). Furthermore, loss of bax prevented
death in bcl-x deﬁcient mice (54) whereas over-expression of
bax in chick embryos increases the susceptibility of sensory
neurons to apoptosis (55). Given the critical role for bax in
controlling death in these neurons, we hypothesize that if
p53 is induced in neuronal progenitor cells or neurons
when Brn-3b is elevated there will be increased apoptosis as
a consequence of elevated Bax. However, if Brn-3a is
expressedathighlevels,itwillrepresspro-apoptoticp53target
genes but cooperate to increase differentiation-associated
genes to enhance cell cycle arrest and survival. Thus when
p53 is induced in these neurons, the relative ratio of Brn-3a to
Brn-3b will be critical in determining cell fate. The resistance
of Brn-3b KO neurons to apoptosis could result either
because Brn-3b is required for maximal induction of bax
in these cells or in the absence of Brn-3b, the related Brn-
3a factor (which may be increased in a compensatory man-
ner) is likely to associate with p53 and repress Bax expres-
sion, even at baseline, with consequent enhanced survival.
Although these hypotheses will need to be tested further,
the opposite expression and antagonistic effects of Brn-3b
and related Brn-3a has previously been observed in neurob-
lastoma cells. Thus, Brn-3b but not Brn-3a is expressed in
proliferating neuroblastoma cells. Upon induction of differen-
tiation by growth of cells in serum free medium, Brn-3b levels
are signiﬁcantly decreased whilst there is a concomitant
increase in Brn-3a expression (4). Moreover, changing the rel-
ative levels of Brn-3a and Brn-3b can alter the growth and
behavior of neuroblastoma cells since forced over-expression
of Brn-3b prevents differentiation of ND7 cells, whereas
increasing Brn-3a induces cell cycle arrest and neurite out-
growth (associated with differentiation) even under growth
conditions that should maintain active proliferation (11,16).
Because of the high homology in the conserved DNA bind-
ing POU domain, Brn-3a and Brn-3b recognize similar DNA
sequences on promoters of target genes. However, there is
very limited similarity outside this region in the full length
protein. These differences contribute to distinct transcrip-
tional effects by these two POU proteins that are dependent
on many factors, including the target gene and cell types.
For instance, whereas Brn-3a can stimulate the expression
of neuronal target genes such as neuroﬁlament, a-internexin,
SNAP 25 and synaptophysin, Brn-3b either represses these
genes and antagonizes the effects of Brn-3a or has no effect
on the promoter activity (15). Thus, although these two tran-
scription factors appear to bind to p53 via their POU domains
and are thus likely to make similar contacts on the DBD of
p53, it is unlikely that their expression would overlap, at
least in neuroblastoma cells, where Brn-3b is expressed
in actively proliferating cells and will be decreased when
Brn-3a is induced upon differentiation. However, it is possi-
ble that in other cell types or during development, there may
be co-expression of Brn-3a and Brn-3b and thus competition
for binding to p53 with consequent changes in cell fate.
Under such circumstances, the relative ratio of Brn-3a to
Brn-3b factors, which depends on the cellular context, will
determine outcome on cellular fate, given the distinct and
opposite effects of Brn-3a and Brn-3b on speciﬁc p53 media-
ted target gene expression.
Brn-3b but not Brn-3a protein is elevated in both breast
cancers and in neuroblastoma tumours (4,6–8). When ele-
vated in these tumours, Brn-3b transcription factor can alter
the growth and behavior of cells by modulating expression
of target genes that help to confer growth advantages to the
cells, e.g. increasing CDK4 (associated cell cycle progres-
sion) and HSP27 (involved in migration and drug resistance)
but represses the tumour suppressor protein, BRCA1
(7,8,18,23,57). However, its ability to alter p53 mediated
effects becomes quite important in these cell types. Although
on its own, Brn-3b represses Bax, when co-expressed with wt
p53 there is cooperative activation to increase bax expression.
This observation is very interesting as it provides a
distinct mechanism by which Brn-3b can act in cancer cells
in response to different conditions. For instance, many
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cytoplasmic sequestration) so does not prevent the initiation
or progression of tumourigenesis (56). Such tumours are
often responsive to chemotherapy that relies on induction
and activation of wtp53 to give rise to apoptosis. Our results
lead us to hypothesize that increasing Brn-3b in cancer cells
promotes growth changes whereas induction of wtp53 (e.g.
by irradiation or chemotherapy) will induce cell cycle arrest
and inhibit growth. When such opposing signals arise in the
cells, they triggers a crisis and cells will undergo apoptosis
instead of proliferation. Such an effect was previously
observedwhentheco-expressionoftheoncogenicMycprotein
with p53 in quiescent cells lead to apoptosis rather than pro-
liferation or cell cycle arrest (58,59). Thus, the ability of
Brn-3b to enhance p53 mediated bax transcription may help
toexplainthemolecularmechanismbywhichcellsthatexpress
wt p53 and Brn-3b, respond to such conﬂicting signals.
Although p53 can transactivate the bax promoter in the
absence of Brn-3b, it is clear that high levels of both Brn-
3b and p53 can signiﬁcantly enhance the expression of this
pro-apoptotic protein in the cells used in this study. The abil-
ity of Brn-3b proteins to associate with and enhance p53
mediated apoptosis in contrast to the related Brn-3a protein,
which prevents apoptosis by p53 and promotes cell cycle
arrest, may prove to be important in understanding how the
molecular responses of p53 can be modiﬁed in different
cell types depending on particular proteins that are co-
expressed with it.
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